Oragenics Extends At-the-Market Equity Sales Agreement

An announcement from Oragenics ( (OGEN) ) is now available.

On January 22, 2026, Oragenics, Inc. amended its existing at-the-market sales agreement, originally entered into on October 11, 2024, with Dawson James Securities Inc. to extend the duration under which it can issue and sell shares of its common stock through the agent on the NYSE American and other permitted methods. The amendment keeps all other terms of the agreement intact while tying its new expiration to the completion of all share sales or the life of the company’s shelf registration statements, a move that preserves Oragenics’ flexibility to raise capital over an extended period and potentially stabilizes its access to funding in volatile market conditions.

Spark’s Take on OGEN Stock

According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.

Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.

To see Spark’s full report on OGEN stock, click here.

More about Oragenics

Oragenics, Inc. is a biotechnology company whose common stock is listed on the NYSE American exchange, using equity offerings as a key financing mechanism to support its operations and growth initiatives in the public markets.

Average Trading Volume: 63,036

Technical Sentiment Signal: Sell

Current Market Cap: $4.04M

For detailed information about OGEN stock, go to TipRanks’ Stock Analysis page.